BMJ Open · Nov 16, 2026
Tirzepatide Titration to Reduce side Effects (TiTRE) in individuals with obesity: a protocol for a randomised controlled trial
By AlOzairi E, Alawadhi A, Alawadhi A et al.
Introduction The epidemic of obesity contributes substantially to non-communicable disease burden and mortality. While nutritional and exercise therapies remain effective for some, the majority of patients may need effective pharmacotherapy and surgical options. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, achieved more than 20% weight loss and improved metabolic outcomes. However, gastrointestinal (GI) adverse events, particularly nausea and vomiting during dose escalation, frequently limit adherence, affecting 65%–84% of patients and leading to discontinuation in some cases. Standard fixed titration schedules fail to account for inter-individual variability in tolerability. Symptom-guided titration may improve adherence by individualising dose escalation but this approach has not been evaluated in randomised trials. Methods and analysis This 76-week, open-label, randomised controlled trial will enrol 68 adults with obesity without diabetes. Participants will be randomised (1:1) to either standard per-label tirzepatide titration or a symptom-guided titration strategy allowing dose adjustments based on tolerability. The primary outcome is time to discontinuation of tirzepatide regimen because of adverse effects over 76 weeks, which captures the cumulative impact of all adverse effects. Secondary outcomes include vomiting frequency, the incidence and severity of individual GI and non-GI adverse effects, discontinuation for any reason, adherence and percentage weight change at 76 weeks. Additional exploratory endpoints include cardiometabolic markers and patient-reported outcomes. Analyses will follow the intention-to-treat principle using appropriate comparative statistical methods. Ethics and dissemination The study has received ethical approval from the Ethical Review Committee, Dasman Diabetes Institute (RA HM-2026-06), and will adhere to Good Clinical Practice guidelines. Written informed consent will be obtained from all participants. Findings will be disseminated through peer-reviewed publications and scientific conferences, with the potential to inform patient-centred dosing strategies and improve long-term outcomes in obesity pharmacotherapy. Trial registration number NCT07574723.